for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quidel Corporation

QDEL.OQ

Latest Trade

245.93USD

Change

-3.44(-1.38%)

Volume

155,457

Today's Range

243.08

 - 

252.62

52 Week Range

55.26

 - 

305.89

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
249.37
Open
252.00
Volume
155,457
3M AVG Volume
23.76
Today's High
252.62
Today's Low
243.08
52 Week High
305.89
52 Week Low
55.26
Shares Out (MIL)
41.95
Market Cap (MIL)
10,316.80
Forward P/E
33.18
Dividend (Yield %)
--

Next Event

Q3 2020 Quidel Corp Earnings Release

Latest Developments

More

Quidel's Lyra Direct SARS-CoV-2 Assay Receives Health Canada Authorization

Quidel Reports Q2 Earnings Per Share $1.55

Quidel Sees Q2 2020 Revenue Of $201 Million To $202 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quidel Corporation

Quidel Corp. is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassays, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of many diseases and medical conditions, including infectious diseases, cardiovascular diseases and conditions, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Amplivue, Lyra and Thyretain.

Industry

Biotechnology & Drugs

Contact Info

9975 Summers Ridge Road

SAN DIEGO, CA

92121

United States

+1.858.5521100

http://www.quidel.com/

Executive Leadership

Kenneth F. Buechler

Independent Chairman of the Board

Douglas C. Bryant

President, Chief Executive Officer, Director

Randall J. Steward

Chief Financial Officer

Robert Joseph Bujarski

Senior Vice President - North America Commercial Operations, General Counsel

Michael Donald Abney

Senior Vice President - Distribution

Key Stats

2.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.5K

2019

0.5K

2020(E)

1.2K
EPS (USD)

2017

0.150

2018

3.040

2019

2.970

2020(E)

11.992
Price To Earnings (TTM)
69.01
Price To Sales (TTM)
15.75
Price To Book (MRQ)
16.87
Price To Cash Flow (TTM)
49.99
Total Debt To Equity (MRQ)
2.10
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
20.30
Return on Equity (TTM)
17.01

Latest News

Latest News

BRIEF-Quidel Sees Q2 2020 Revenue Of $201 Million To $202 Million

* QUIDEL ANNOUNCES PRELIMINARY REVENUE FOR SECOND QUARTER 2020

BRIEF-Quidel Receives Barda Funding To Develop Point-Of-Care Diagnostic Assay That Includes COVID-19

* QUIDEL RECEIVES BARDA FUNDING TO DEVELOP POINT-OF-CARE DIAGNOSTIC ASSAY THAT INCLUDES COVID-19

BRIEF-Quidel Receives Amended Emergency Authorization For Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument

* QUIDEL RECEIVES AMENDED EMERGENCY AUTHORIZATION FOR RAPID ANTIGEN COVID-19 DIAGNOSTIC ASSAY USING SOFIA 1 INSTRUMENT

BRIEF-Quidel's LyraDirect SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step

* QUIDEL’S LYRA® DIRECT SARS-COV-2 ASSAY RECEIVES EMERGENCY USE AUTHORIZATION AND CE MARK FOR MOLECULAR DETECTION OF COVID-19, WITHOUT EXTRACTION STEP Source text for Eikon: Further company coverage:

FDA grants emergency use authorization to Quidel for first antigen test for COVID-19

The U.S. Food and Drug Administration (FDA) on Saturday approved emergency use authorization (EUA) to Quidel Corp <QDEL.O> for the first COVID-19 antigen test.

U.S. FDA grants emergency use authorization to Quidel for first antigen test for COVID-19

The U.S. Food and Drug Administration (FDA) on Saturday approved emergency use authorization (EUA) to Quidel Corp for the first COVID-19 antigen test.

BRIEF-Quidel Receives Emergency Authorization For Rapid Antigen Covid-19 Diagnostic Assay

* QUIDEL RECEIVES EMERGENCY AUTHORIZATION FOR RAPID ANTIGEN COVID-19 DIAGNOSTIC ASSAY

BRIEF-Quidel Reports First Quarter 2020 Financial Results

* Q1 REVENUE $174.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $160.7 MILLION

BRIEF-Quidel's Lyra Direct Sars-Cov-2 Assay Submitted For Emergency Use Authorization For Molecular Detection Of Covid-19, Without Extraction Step

* QUIDEL’S LYRA® DIRECT SARS-COV-2 ASSAY SUBMITTED FOR EMERGENCY USE AUTHORIZATION FOR MOLECULAR DETECTION OF COVID-19, WITHOUT EXTRACTION STEP Source text for Eikon: Further company coverage:

BRIEF-Quidel Corp Says Lyra Sars-Cov-2 Assay Has Received Expanded Emergency Use Authorization Claims From FDA

* LYRA SARS-COV-2 ASSAY HAS RECEIVED EXPANDED EMERGENCY USE AUTHORIZATION (EUA) CLAIMS FROM FOOD AND DRUG ADMINISTRATION

BRIEF-Quidel Receives Emergency Use Authorization For Molecular Covid-19 Diagnostic Assay

* QUIDEL RECEIVES EMERGENCY USE AUTHORIZATION FOR MOLECULAR COVID-19 DIAGNOSTIC ASSAY

BRIEF-Quidel Reports Fourth Quarter And Full Year 2019 Financial Results

* QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Quidel Reports Q1 Non-GAAP Earnings Per Share $1.29

* Q1 REVENUE $169.1 MILLION VERSUS I/B/E/S VIEW $150.9 MILLION

BRIEF-Quidel Corp Says Increased Size Of Board To Eight Members - SEC Filing

* QUIDEL CORP SAYS INCREASED SIZE OF COMPANY'S BOARD OF DIRECTORS TO EIGHT MEMBERS - SEC FILING Source text (https://bit.ly/2q4dLBG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Quidel Receives FDA Clearance For Its Instrument

* QUIDEL RECEIVES FDA CLEARANCE FOR ITS POINT-OF-CARE SOFIA® LYME FLUORESCENT IMMUNOASSAY FOR USE WITH SOFIA® 2 INSTRUMENT Source text for Eikon: Further company coverage:

BRIEF-Quidel Q4 Non-Gaap Earnings Per Share $0.56

* QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Quidel Receives 510(K) Clearance For Quickvue Influenza A+B Test

* QUIDEL RECEIVES 510(K) CLEARANCE FOR QUICKVUE INFLUENZA A+B TEST, ASSAY MEETS FDA'S CLASS II RIDT REQUIREMENTS

BRIEF-Quidel Receives FDA Clearance And Clia Waiver For Its Point-Of-Care Sofia® 2 Instrument

* QUIDEL RECEIVES FDA CLEARANCE AND CLIA WAIVER FOR ITS POINT-OF-CARE SOFIA® 2 INSTRUMENT FOR USE WITH SOFIA STREP A+ ASSAY Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

BRIEF-Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

* QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS

BRIEF-Quidel Corp reports Q3 GAAP loss per share $0.16

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up